Activity of enzymes of a sphingomyelin cycle and concentration of products of sphingomyelin degradation in the liver of rats in dynamics of the acute toxic hepatitis

Serebrov, V. Yu.; Kuzmenko, D. I.; Burov, P. G.; Sapugol'tseva, O B

doi:10.18097/pbmc20105602283

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PC participated in the repair of cell membranes and promoted the generation of choline to synthesize GSH acting as antioxidant, so PC showed the downtrend and its degradation products showed the same trend. Some studies have found that FA is the major energy resource under pressure [58]. It could provide energy for hepatocyte to facilitate its function by β -oxidation.…”

Section: Discussionmentioning

confidence: 99%

Metabonomics Research Progress on Liver Diseases

Zhu

Cong

et al. 2017

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

Metabolomics as the new omics technique develops after genomics, transcriptomics, and proteomics and has rapid development at present. Liver diseases are worldwide public health problems. In China, chronic hepatitis B and its secondary diseases are the common liver diseases. They can be diagnosed by the combination of history, virology, liver function, and medical imaging. However, some patients seldom have relevant physical examination, so the diagnosis may be delayed. Many other liver diseases, such as drug-induced liver injury (DILI), alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD), and autoimmune liver diseases, still do not have definite diagnostic markers; the diagnosis consists of history, medical imaging, and the relevant score. As a result, the clinical work becomes very complex. So it has broad prospects to explore the specific and sensitive biomarkers of liver diseases with metabolomics. In this paper, there are several summaries which are related to the current research progress and application of metabolomics on biomarkers of liver diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Metabonomics Research Progress on Liver Diseases

Zhu

Cong

et al. 2017

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

show abstract

Efficacy of Fluidized Bed Bioartificial Liver in Treating Fulminant Hepatic Failure in Pigs: A Metabolomics Study

Zhou

Shao

Zhao

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Bioartificial livers may act as a promising therapy for fulminant hepatic failure (FHF) with better accessibility and less injury compared to orthotopic liver transplantation. This study aims to evaluate the efficacy and safety of a fluidized bed bioartificial liver (FBBAL) and to explore its therapeutic mechanisms based on metabolomics. FHF was induced by D-galactosamine. Eighteen hours later, pigs were treated with an FBBAL containing encapsulated primary porcine hepatocytes (B group), with a sham FBBAL (containing cell-free capsules, S group) or with only intensive care (C group) for 6 h. Serum samples were assayed using ultra-performance liquid chromatography-mass spectrometry. The difference in survival time (51.6 ± 7.9 h vs. 49.3 ± 6.6 h) and serum metabolome was negligible between the S and C groups, whereas FBBAL treatment significantly prolonged survival time (70.4 ± 11.5h, P < 0.01) and perturbed the serum metabolome, resulting in a marked decrease in phosphatidylcholines, lysophosphatidylcholines, sphingomyelinase, and fatty acids and an increase in conjugated bile acids. The FBBAL exhibits some liver functions and may exert its therapeutic effect by altering the serum metabolome of FHF pigs. Moreover, alginate–chitosan capsules have less influence on serum metabolites. Nevertheless, the alterations were not universally beneficial, revealing that much should be done to improve the FBBAL.

show abstract

Activity of enzymes of a sphingomyelin cycle and concentration of products of sphingomyelin degradation in the liver of rats in dynamics of the acute toxic hepatitis

Cited by 2 publications

References 6 publications

Metabonomics Research Progress on Liver Diseases

Metabonomics Research Progress on Liver Diseases

Efficacy of Fluidized Bed Bioartificial Liver in Treating Fulminant Hepatic Failure in Pigs: A Metabolomics Study

Contact Info

Product

Resources

About